ä-/-ä 2020[Apr]; 20 (2): 108-17 PMIDC7144845show ga
Background: COVID-19 is part of the family of viruses known as Coronaviridae. The new pathogen ?-coronavirus of the subgenus Sarbecovirus was initially named as a novel coronavirus (2019-nCoV), identified in a pneumonia outbreak in Wuhan. Patients developed alterations in the respiratory system leading to severe pneumonia, pulmonary oedema, and acute respiratory distress syndrome. Objective: To review the available scientific evidence related to the care of the respiratory system in order to establish general treatment guidelines. Methods: Narrative review of the literature was carried out that included a search, selection, and review of original and secondary articles written in English or Spanish in the different databases: NCBI, CENTRAL, MEDLINE and EMBASE published up to March 2020. Results: No specific treatment for the new disease has been defined, with symptomatic control as the main therapeutic measure. The use of biosecurity elements, such as goggles, hats, gloves, long waterproof aprons, high efficiency masks for healthcare personnel (FFP2 or N95) is recommended. In symptomatic patients use surgical masks, hospital soap, paper towels, and 70% alcohol or isopropyl alcohol. Use oxygen through low flow systems. A mechanical ventilation program in VCP or VCV modes, Vt 4-6 ml/Kg, Fr ? 35, FiO2 for PaO2 = 60 mmHg or SpO2 92-96%, PEEP 12-17 cmH2O, prone ventilation if PAFI ? 150 with ratio 16/8 or 18/6, nitric oxide 5-20 ppm. Conclusions: Use biosecurity equipment in order to prevent transmission. In hypoxaemia use low flow oxygen therapy systems. Use lung protection strategies, decrease in tidal volumes, plateau pressures and respiratory rates, plus implementation of high PEEP values, low conduction pressure values and prone ventilation. These have been shown to improve hypoxaemia and survival in patients with acute respiratory distress syndrome.
free
free
free
ä-/-ä 2020 ; 20 (2): 108-17
